首页> 外文OA文献 >Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy

【2h】

Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy

机译：丙型肝炎病毒（HCV）肝移植受者的肝细胞癌复发，用预体直接作用抗病毒（DAA）治疗治疗

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Nicholas Lim; Dupinder Singh; Scott Jackson; John R. Lake;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Impact of Hepatocellular Carcinoma (HCC) and Tumor Treatment on Sustained Virologic Response (SVR) Rates with Direct-Acting Antiviral (DAA) Therapy for Hepatitis C: HCV-TARGET Results [J] . Radhakrishnan Kavita, Di Bisceglie Adrian M., Reddy K. Rajender, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：肝细胞癌（HCC）的影响和肿瘤治疗对丙型肝炎直接作用抗病毒（DAA）治疗的持续病毒性反应（SVR）率的影响：HCV-靶结果
2. TREATMENT WITH DIRECT-ACTING ANTIVIRALS (DAAS) NEITHER INCREASES THE RISK OF HEPATOCELLULAR CARCINOMA PROGRESSION DURING WAITING LIST NOR RECURRENCE AFTER LIVER TRANSPLANTATION [J] . Pinero Federico, Boin Ilka, Rubinstein Fernando, Transplant international : . 2019,第S2期

机译：用直效抗病毒治疗（DAAs）既不会增加肝移植后等待清单中肝细胞癌进展的风险，也不会复发
3. Hepatocellular carcinoma after direct-acting antiviral therapy in kidney transplant recipients infected with hepatitis C virus [J] . Rita Cal?a, Cristina Jorge, Luís Lebre, Nefrologia . 2020,第6期

机译：肝细胞癌患有丙型肝炎病毒的肾移植受者直接作用抗病毒治疗后
4. Herbal Medicine Containing Aristolochic Acid and the Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Infection: A Nationwide Population-Based Cohort Study in Taiwan [C] . Wen-Chao Ho, Chi-Jen Chen, Yao-Hsu Yang, Joint annual meeting of the International Society of Exposure Science and the International Society for Environmental Epidemiology . 2018

机译：含有马兜铃酸的草药和丙型肝炎病毒感染患者肝细胞癌的风险：台湾全国性人群研究
5. Analyzing the Impact of the CMS Guidance on Assuring Access to Hepatitis C Virus (HCV) Drugs on Utilization of Direct-Acting Antiviral (DAA) Agents [D] . Ferrell, Kelli Walker. 2017

机译：分析CMS指南对确保获得丙型肝炎病毒（HCV）药物对直接作用抗病毒（DAA）药物利用的影响
6. Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy [O] . Nicholas Lim, Dupinder Singh, Scott Jackson, 2020

机译：丙型肝炎病毒（HCV）肝移植受者的肝细胞癌复发用预体直接作用抗病毒（DAA）治疗治疗
7. Rates of sustained virological response 12 weeks after the scheduled end of direct-acting antiviral (DAA)-based hepatitis C virus (HCV) therapy from the National German HCV registry: does HIV coinfection impair the response to DAA combination therapy? [O] . J Bischoff, S Mauss, C Cordes, 2018

机译：直接作用抗病毒（DAA）的丙型肝炎病毒（HCV）治疗的预定结束后12周持续持续的病毒学响应率：HIV繁殖会损害对DAA组合治疗的反应吗？

Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy

著录项

相似文献

相关主题

期刊订阅